Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma

Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study

(2013) Richard MA Follows et al.   RESPIRATORY RESEARCH

The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma

(2011) Yasmine S. Wasfi et al.   RESPIRATORY MEDICINE

Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation

(2010) Daniel S. Lorrain et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Step-up Therapy for Children with Uncontrolled Asthma Receiving Inhaled Corticosteroids

(2010) Robert F. Lemanske et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study

(2009) Dana Korn et al.   CURRENT MEDICAL RESEARCH AND OPINION

Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250μg/Salmeterol 50μg

(2009) Arthur F. Gelb et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS